Merck announced second-quarter 2004 earnings per share of 79 cents, level with the prior year. Worldwide sales grew 9% to $6 billion for the quarter. Merck reaffirmed its full-year 2004 EPS guidance of $3.11 to $3.17 and anticipated third-quarter EPS of 80 to 84 cents. Key pipeline developments included MK-431 entering Phase III trials for diabetes and positive data for ROTATEQ, Merck's investigational rotavirus vaccine. Merck continued strategic licensing deals, including collaborations for diabetes compound muraglitazar and cancer compound VX-680.
Merck announced first-quarter 2004 earnings per share of $0.73, a 7% increase over the previous year. Worldwide sales were $5.6 billion for the quarter. Merck reaffirmed its full-year 2004 EPS guidance of $3.11 to $3.17. Key events in the quarter included acquiring Aton Pharma and completing the acquisition of Banyu Pharmaceutical, strengthening Merck's global position. Sales of major products like Zocor, Fosamax, Cozaar, and Singulair increased compared to the previous year.
Merck announced third quarter 2005 earnings per share of $0.65. Merck anticipates full-year 2005 EPS to be between $2.47 to $2.51, excluding a tax charge, or $2.18 to $2.22 including the charge. Key drug franchises like Singulair, Cozaar/Hyzaar, and Fosamax maintained sales leadership. Merck's pipeline progressed with positive Phase III data for the HPV vaccine Gardasil and Phase II data for the diabetes drug sitagliptin. Merck formed new partnerships including one with Agensys to develop a prostate cancer antibody.
Merck announced third-quarter 2004 earnings per share of 60 cents, including a 25 cent unfavorable impact from withdrawing Vioxx worldwide. Merck anticipates fourth-quarter EPS of 48-53 cents and full-year 2004 EPS of $2.59-$2.64 due to withdrawing Vioxx. Several drug trials showed positive results and new products like Vytorin were launched, but Vioxx sales of $2.5 billion last year will significantly impact finances. Merck is redeploying resources and finding other growth areas.
Merck announced earnings per share of $2.92 for full-year 2003 and $0.62 for the fourth quarter of 2003. Sales increased 5% for the full year but decreased 7% for the fourth quarter due to Merck's new US distribution program. Merck reaffirmed its 2004 EPS guidance of $3.11 to $3.17. Key products like Zocor, Fosamax, Cozaar, Singulair and Vioxx remained top sellers, though some faced increased competition or effects from the new distribution program. Merck's research pipeline includes potential new vaccines and treatments for conditions like diabetes and Alzheimer's.
Merck announced strong financial results for the first quarter of 2006, with earnings per share of $0.78 excluding restructuring charges. Solid performance of key drugs like ZOCOR, SINGULAIR and vaccines, along with partnerships, drove earnings. Merck raised full-year 2006 guidance, now anticipating EPS between $2.32-$2.40 excluding charges. Performance of major franchises like SINGULAIR, COZAAR/HYZAAR and FOSAMAX was mixed, with US sales remaining strong but international sales declining due to generics.
Merck announced strong financial results for the second quarter of 2006, with earnings per share of $0.73 excluding restructuring charges. Revenue increased 6% to $5.8 billion driven by strong sales of drugs like ZOCOR, SINGULAIR, and vaccines. Merck also gained FDA approval for new vaccines GARDASIL and ZOSTAVAX, and raised full-year 2006 guidance. In addition, the company reported progress on drugs in development like JANUVIA and ZOLINZA.
Merck announced full-year 2004 earnings per share of $2.61, with fourth-quarter EPS of 50 cents. Merck reaffirmed its 2005 EPS guidance range of $2.42 to $2.52, and anticipated first-quarter 2005 EPS of 54 to 58 cents. Merck increased its reserve for future legal defense costs related to VIOXX litigation to $675 million. Merck's major product franchises, including Singulair, Fosamax, Cozaar/Hyzaar, Zocor, and the cholesterol-lowering drugs Zetia and Vytorin in partnership with Schering-Plough, remained market leaders.
Merck announced strong financial results for Q3 2006, with EPS of $0.51 including additional legal defense costs for VYTORIN lawsuits. Key drugs like SINGULAIR, VYTORIN, and vaccines performed well. Full-year 2006 EPS guidance was raised to a range of $2.48-$2.52 excluding restructuring charges. The FDA approved two new drugs, JANUVIA for diabetes and ZOLINZA for skin cancer treatment. Pipeline programs for HIV and insomnia treatments were updated.
Merck announced first-quarter 2004 earnings per share of $0.73, a 7% increase over the previous year. Worldwide sales were $5.6 billion for the quarter. Merck reaffirmed its full-year 2004 EPS guidance of $3.11 to $3.17. Key events in the quarter included acquiring Aton Pharma and completing the acquisition of Banyu Pharmaceutical, strengthening Merck's global position. Sales of major products like Zocor, Fosamax, Cozaar, and Singulair increased compared to the previous year.
Merck announced third quarter 2005 earnings per share of $0.65. Merck anticipates full-year 2005 EPS to be between $2.47 to $2.51, excluding a tax charge, or $2.18 to $2.22 including the charge. Key drug franchises like Singulair, Cozaar/Hyzaar, and Fosamax maintained sales leadership. Merck's pipeline progressed with positive Phase III data for the HPV vaccine Gardasil and Phase II data for the diabetes drug sitagliptin. Merck formed new partnerships including one with Agensys to develop a prostate cancer antibody.
Merck announced third-quarter 2004 earnings per share of 60 cents, including a 25 cent unfavorable impact from withdrawing Vioxx worldwide. Merck anticipates fourth-quarter EPS of 48-53 cents and full-year 2004 EPS of $2.59-$2.64 due to withdrawing Vioxx. Several drug trials showed positive results and new products like Vytorin were launched, but Vioxx sales of $2.5 billion last year will significantly impact finances. Merck is redeploying resources and finding other growth areas.
Merck announced earnings per share of $2.92 for full-year 2003 and $0.62 for the fourth quarter of 2003. Sales increased 5% for the full year but decreased 7% for the fourth quarter due to Merck's new US distribution program. Merck reaffirmed its 2004 EPS guidance of $3.11 to $3.17. Key products like Zocor, Fosamax, Cozaar, Singulair and Vioxx remained top sellers, though some faced increased competition or effects from the new distribution program. Merck's research pipeline includes potential new vaccines and treatments for conditions like diabetes and Alzheimer's.
Merck announced strong financial results for the first quarter of 2006, with earnings per share of $0.78 excluding restructuring charges. Solid performance of key drugs like ZOCOR, SINGULAIR and vaccines, along with partnerships, drove earnings. Merck raised full-year 2006 guidance, now anticipating EPS between $2.32-$2.40 excluding charges. Performance of major franchises like SINGULAIR, COZAAR/HYZAAR and FOSAMAX was mixed, with US sales remaining strong but international sales declining due to generics.
Merck announced strong financial results for the second quarter of 2006, with earnings per share of $0.73 excluding restructuring charges. Revenue increased 6% to $5.8 billion driven by strong sales of drugs like ZOCOR, SINGULAIR, and vaccines. Merck also gained FDA approval for new vaccines GARDASIL and ZOSTAVAX, and raised full-year 2006 guidance. In addition, the company reported progress on drugs in development like JANUVIA and ZOLINZA.
Merck announced full-year 2004 earnings per share of $2.61, with fourth-quarter EPS of 50 cents. Merck reaffirmed its 2005 EPS guidance range of $2.42 to $2.52, and anticipated first-quarter 2005 EPS of 54 to 58 cents. Merck increased its reserve for future legal defense costs related to VIOXX litigation to $675 million. Merck's major product franchises, including Singulair, Fosamax, Cozaar/Hyzaar, Zocor, and the cholesterol-lowering drugs Zetia and Vytorin in partnership with Schering-Plough, remained market leaders.
Merck announced strong financial results for Q3 2006, with EPS of $0.51 including additional legal defense costs for VYTORIN lawsuits. Key drugs like SINGULAIR, VYTORIN, and vaccines performed well. Full-year 2006 EPS guidance was raised to a range of $2.48-$2.52 excluding restructuring charges. The FDA approved two new drugs, JANUVIA for diabetes and ZOLINZA for skin cancer treatment. Pipeline programs for HIV and insomnia treatments were updated.
Merck reported double-digit earnings per share growth for the second quarter of 2007, driven by strong performance of key products. EPS excluding restructuring charges were $0.82, up 12% from the prior year. Sales increased 6% to $6.1 billion for the quarter. Merck raised its full-year 2007 EPS guidance to a range of $3.00 to $3.10 excluding restructuring charges. Best-selling products like Singulair, Januvia, and vaccines contributed significantly to revenue growth.
Type ii diabetes case study for Drug LaunchKoushik Sircar
An attempt to provide a brief on Market Entry for New Add-On Drug ( Secondary Care) within Type-II Diabetes Market- focused on Add-on Drugs Data Analysis, Visualizations, Growth Share Matrix and Frameworks for Market Entry
The document provides an overview of Sanofi's Q4 and full year 2021 results. Key highlights include:
- Global sales grew 7.1% in 2021 to €37.7 billion, driven by strong growth of Specialty Care which became the largest business unit.
- Dupixent sales increased 53% in Q4 to €1.55 billion, with growth across all regions. Prurigo nodularis phase 3 trials showed significant improvements.
- Vaccines sales declined 6.5% in Q4 due to earlier seasonal flu shipments, while full year flu vaccine sales reached record levels in 2021.
- Planned launches of sutimlimab for CAD in 2022 and olp
COVID-19 and its Impact on the Biopharma Financing and Deal EnvironmentTim Opler
The document provides an overview of the impact of the COVID-19 pandemic on the biopharmaceutical sector. It discusses the direct impact on the pharmaceutical industry, including decreased healthcare utilization, clinical trial delays, supply chain issues, and decreased drug usage and revenue. It also covers the indirect effects, such as potential government budget constraints, drug price pressures, increased social division, and response from regulators to encourage testing and device approvals during the pandemic.
Trends in Oncology Pharmaceuticals Business DevelopmentTim Opler
This presentation provides an overview of the evolving marketplace for oncology transactions and is a summary of discussion materials shared by Torreya at the Sachs Conference on September 26, 2019 in Basel, Switzerland.
This document discusses Sanofi's Q4 and full year 2018 results. It provides an agenda for the presentation and highlights key metrics:
- Q4 sales grew 4.7% at CER to €8.997 billion and EPS grew to €1.10. Full year sales grew 2.5% at CER to €34.463 billion.
- Specialty care sales grew 16.1% in Q4 driven by rare disease, MS, immunology and oncology franchises. Vaccines sales grew 9.7% in Q4.
- Dupixent sales accelerated in Q4 with a 25% increase in prescriptions in the US market due to direct-to-consumer campaigns
Merck announced second-quarter 2005 earnings per share of 33 cents, down from 79 cents in 2004 due to a $640 million net tax charge. Excluding this charge, EPS were 62 cents. Worldwide sales were $5.5 billion, down 9% from 2004 due to the Vioxx withdrawal. Merck anticipates third-quarter EPS of 61-65 cents and full-year 2005 EPS of $2.44-$2.52 excluding the tax charge. Major drug franchises like Singulair, Fosamax, Cozaar, and Zocor maintained or grew market share. Merck's vaccine and diabetes drug pipelines progressed with regulatory submissions.
GSK reported financial results for the third quarter of 2008. Revenue declined 3% due to generic competition impacting major pharmaceutical brands in the US, though other areas like vaccines and emerging markets saw growth. Earnings per share declined 9% due to higher costs of sales from generic competition. The company increased its dividend by 8% and continued share repurchases while pursuing strategic priorities like diversifying its business and expanding in emerging markets and consumer healthcare.
Sanofi reported its Q2 2020 results, highlighting a 9.2% increase in EPS driven by strong Dupixent sales growth of 94%. While most business units saw impacts from COVID-19, Dupixent maintained momentum with new launches and indications. Sanofi also progressed its pipeline including initiating Phase 3 for BTK inhibitor '168 in multiple sclerosis.
- Sanofi reported Q3 2020 results with total sales of €9.5 billion, up 5.7% year-over-year at CER.
- Dupixent sales grew 69% to €918 million driven by strong performance in atopic dermatitis and asthma.
- Vaccines sales increased 14% to €2.1 billion due to a record flu season with over 80 million doses delivered in the US.
- General Medicines sales declined 7% to €3.6 billion due to anticipated price impacts in China, while Diabetes sales declined by low single digits globally.
This document contains forward-looking statements regarding Sanofi's strategic outlook, key growth drivers, and pipeline of potential transformative therapies. It discusses the significant growth potential of Dupixent across type 2 inflammatory diseases, with an ambition to achieve over €10 billion in peak sales. Vaccines are also highlighted as an expected mid-to-high single-digit growth driver through 2025. The pipeline includes potential first-in-class or best-in-class therapies for diseases like multiple sclerosis, respiratory syncytial virus, and breast cancer that could transform patient care if approved.
This document provides an agenda and key highlights from Sanofi's Q1 2019 results presentation:
- The presentation reviews Sanofi's Q1 2019 financial results, with sales increasing 4.2% and EPS growth of 9.4% driven by launches and diminishing LoEs in the US.
- Several business units saw double-digit growth including Genzyme, Vaccines, and China/Emerging Markets, partially offset by lower sales of Diabetes and Established Products.
- The pipeline highlights potential approvals over the next year including Dupixent in additional indications and geographies as well as Zynquista and Cemiplimab.
MolMed Approved The Interim Financial Report At 30 September 2013social_molmed
The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013. The most important elements were: TK: expansion in the US of the pivotal Phase III trial for high-risk leukaemia patients; NGR-TNF: continuation of the clinical development program; the increase of revenues to € 3.1 million from development of new cell and gene therapy treatments for third parties.
- Jean-Baptiste de Chatillon presented at the JP Morgan Healthcare Conference on January 8, 2019.
- He discussed Sanofi's strategic transformation including launching new products, reshaping their portfolio through acquisitions and divestitures, and simplifying their organization.
- Key products discussed included Dupixent's expansion in new indications and geographies, positive data for Dupixent in nasal polyps, and the US launch of Libtayo for skin cancer.
- Sanofi is also building their leadership in rare blood disorders through recent acquisitions and their hemophilia and thrombosis drug pipelines.
This document provides an overview of Sanofi's Q4 and full year 2020 results. Some key highlights include:
- Q4 sales grew 4.2% driven by strong growth of Dupixent and vaccines. Full year sales grew 3.3%.
- Business operating income margin increased in Q4 and for the full year, trending towards 2022 targets.
- Free cash flow grew significantly to €7 billion in 2020 through business performance, cost savings initiatives, and asset sales.
- A dividend of €3.20 per share is proposed, representing the 27th consecutive year of dividend growth.
- Q1 2020 sales were €8.973 billion, up 6.6% driven by strong Dupixent sales growth.
- Dupixent sales increased 130% to €776 million and continue to see double-digit growth.
- Specialty Care sales were up 31.3% led by Dupixent while General Medicines sales fell 3.8% due to COVID-19 stocking and China's VBP program.
The website www.larryhamill.com features photographs of aircraft in action. Larry Hamill has captured planes taking off, landing, and flying maneuvers. Visitors to the site can browse and purchase Hamill's photos showcasing the excitement and beauty of aircraft in flight.
In the summer of 2010 I painted some used cameras and had friends pose with them. I merged those images with a variety of backgrounds I created on the computer.
http://inarocket.com
Learn BEM fundamentals as fast as possible. What is BEM (Block, element, modifier), BEM syntax, how it works with a real example, etc.
Merck reported double-digit earnings per share growth for the second quarter of 2007, driven by strong performance of key products. EPS excluding restructuring charges were $0.82, up 12% from the prior year. Sales increased 6% to $6.1 billion for the quarter. Merck raised its full-year 2007 EPS guidance to a range of $3.00 to $3.10 excluding restructuring charges. Best-selling products like Singulair, Januvia, and vaccines contributed significantly to revenue growth.
Type ii diabetes case study for Drug LaunchKoushik Sircar
An attempt to provide a brief on Market Entry for New Add-On Drug ( Secondary Care) within Type-II Diabetes Market- focused on Add-on Drugs Data Analysis, Visualizations, Growth Share Matrix and Frameworks for Market Entry
The document provides an overview of Sanofi's Q4 and full year 2021 results. Key highlights include:
- Global sales grew 7.1% in 2021 to €37.7 billion, driven by strong growth of Specialty Care which became the largest business unit.
- Dupixent sales increased 53% in Q4 to €1.55 billion, with growth across all regions. Prurigo nodularis phase 3 trials showed significant improvements.
- Vaccines sales declined 6.5% in Q4 due to earlier seasonal flu shipments, while full year flu vaccine sales reached record levels in 2021.
- Planned launches of sutimlimab for CAD in 2022 and olp
COVID-19 and its Impact on the Biopharma Financing and Deal EnvironmentTim Opler
The document provides an overview of the impact of the COVID-19 pandemic on the biopharmaceutical sector. It discusses the direct impact on the pharmaceutical industry, including decreased healthcare utilization, clinical trial delays, supply chain issues, and decreased drug usage and revenue. It also covers the indirect effects, such as potential government budget constraints, drug price pressures, increased social division, and response from regulators to encourage testing and device approvals during the pandemic.
Trends in Oncology Pharmaceuticals Business DevelopmentTim Opler
This presentation provides an overview of the evolving marketplace for oncology transactions and is a summary of discussion materials shared by Torreya at the Sachs Conference on September 26, 2019 in Basel, Switzerland.
This document discusses Sanofi's Q4 and full year 2018 results. It provides an agenda for the presentation and highlights key metrics:
- Q4 sales grew 4.7% at CER to €8.997 billion and EPS grew to €1.10. Full year sales grew 2.5% at CER to €34.463 billion.
- Specialty care sales grew 16.1% in Q4 driven by rare disease, MS, immunology and oncology franchises. Vaccines sales grew 9.7% in Q4.
- Dupixent sales accelerated in Q4 with a 25% increase in prescriptions in the US market due to direct-to-consumer campaigns
Merck announced second-quarter 2005 earnings per share of 33 cents, down from 79 cents in 2004 due to a $640 million net tax charge. Excluding this charge, EPS were 62 cents. Worldwide sales were $5.5 billion, down 9% from 2004 due to the Vioxx withdrawal. Merck anticipates third-quarter EPS of 61-65 cents and full-year 2005 EPS of $2.44-$2.52 excluding the tax charge. Major drug franchises like Singulair, Fosamax, Cozaar, and Zocor maintained or grew market share. Merck's vaccine and diabetes drug pipelines progressed with regulatory submissions.
GSK reported financial results for the third quarter of 2008. Revenue declined 3% due to generic competition impacting major pharmaceutical brands in the US, though other areas like vaccines and emerging markets saw growth. Earnings per share declined 9% due to higher costs of sales from generic competition. The company increased its dividend by 8% and continued share repurchases while pursuing strategic priorities like diversifying its business and expanding in emerging markets and consumer healthcare.
Sanofi reported its Q2 2020 results, highlighting a 9.2% increase in EPS driven by strong Dupixent sales growth of 94%. While most business units saw impacts from COVID-19, Dupixent maintained momentum with new launches and indications. Sanofi also progressed its pipeline including initiating Phase 3 for BTK inhibitor '168 in multiple sclerosis.
- Sanofi reported Q3 2020 results with total sales of €9.5 billion, up 5.7% year-over-year at CER.
- Dupixent sales grew 69% to €918 million driven by strong performance in atopic dermatitis and asthma.
- Vaccines sales increased 14% to €2.1 billion due to a record flu season with over 80 million doses delivered in the US.
- General Medicines sales declined 7% to €3.6 billion due to anticipated price impacts in China, while Diabetes sales declined by low single digits globally.
This document contains forward-looking statements regarding Sanofi's strategic outlook, key growth drivers, and pipeline of potential transformative therapies. It discusses the significant growth potential of Dupixent across type 2 inflammatory diseases, with an ambition to achieve over €10 billion in peak sales. Vaccines are also highlighted as an expected mid-to-high single-digit growth driver through 2025. The pipeline includes potential first-in-class or best-in-class therapies for diseases like multiple sclerosis, respiratory syncytial virus, and breast cancer that could transform patient care if approved.
This document provides an agenda and key highlights from Sanofi's Q1 2019 results presentation:
- The presentation reviews Sanofi's Q1 2019 financial results, with sales increasing 4.2% and EPS growth of 9.4% driven by launches and diminishing LoEs in the US.
- Several business units saw double-digit growth including Genzyme, Vaccines, and China/Emerging Markets, partially offset by lower sales of Diabetes and Established Products.
- The pipeline highlights potential approvals over the next year including Dupixent in additional indications and geographies as well as Zynquista and Cemiplimab.
MolMed Approved The Interim Financial Report At 30 September 2013social_molmed
The Board of Directors of MolMed S.p.A., chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 30 September 2013. The most important elements were: TK: expansion in the US of the pivotal Phase III trial for high-risk leukaemia patients; NGR-TNF: continuation of the clinical development program; the increase of revenues to € 3.1 million from development of new cell and gene therapy treatments for third parties.
- Jean-Baptiste de Chatillon presented at the JP Morgan Healthcare Conference on January 8, 2019.
- He discussed Sanofi's strategic transformation including launching new products, reshaping their portfolio through acquisitions and divestitures, and simplifying their organization.
- Key products discussed included Dupixent's expansion in new indications and geographies, positive data for Dupixent in nasal polyps, and the US launch of Libtayo for skin cancer.
- Sanofi is also building their leadership in rare blood disorders through recent acquisitions and their hemophilia and thrombosis drug pipelines.
This document provides an overview of Sanofi's Q4 and full year 2020 results. Some key highlights include:
- Q4 sales grew 4.2% driven by strong growth of Dupixent and vaccines. Full year sales grew 3.3%.
- Business operating income margin increased in Q4 and for the full year, trending towards 2022 targets.
- Free cash flow grew significantly to €7 billion in 2020 through business performance, cost savings initiatives, and asset sales.
- A dividend of €3.20 per share is proposed, representing the 27th consecutive year of dividend growth.
- Q1 2020 sales were €8.973 billion, up 6.6% driven by strong Dupixent sales growth.
- Dupixent sales increased 130% to €776 million and continue to see double-digit growth.
- Specialty Care sales were up 31.3% led by Dupixent while General Medicines sales fell 3.8% due to COVID-19 stocking and China's VBP program.
The website www.larryhamill.com features photographs of aircraft in action. Larry Hamill has captured planes taking off, landing, and flying maneuvers. Visitors to the site can browse and purchase Hamill's photos showcasing the excitement and beauty of aircraft in flight.
In the summer of 2010 I painted some used cameras and had friends pose with them. I merged those images with a variety of backgrounds I created on the computer.
http://inarocket.com
Learn BEM fundamentals as fast as possible. What is BEM (Block, element, modifier), BEM syntax, how it works with a real example, etc.
How to Build a Dynamic Social Media PlanPost Planner
Stop guessing and wasting your time on networks and strategies that don’t work!
Join Rebekah Radice and Katie Lance to learn how to optimize your social networks, the best kept secrets for hot content, top time management tools, and much more!
Watch the replay here: bit.ly/socialmedia-plan
The document discusses how personalization and dynamic content are becoming increasingly important on websites. It notes that 52% of marketers see content personalization as critical and 75% of consumers like it when brands personalize their content. However, personalization can create issues for search engine optimization as dynamic URLs and content are more difficult for search engines to index than static pages. The document provides tips for SEOs to help address these personalization and SEO challenges, such as using static URLs when possible and submitting accurate sitemaps.
Lightning Talk #9: How UX and Data Storytelling Can Shape Policy by Mika Aldabaux singapore
How can we take UX and Data Storytelling out of the tech context and use them to change the way government behaves?
Showcasing the truth is the highest goal of data storytelling. Because the design of a chart can affect the interpretation of data in a major way, one must wield visual tools with care and deliberation. Using quantitative facts to evoke an emotional response is best achieved with the combination of UX and data storytelling.
This document summarizes a study of CEO succession events among the largest 100 U.S. corporations between 2005-2015. The study analyzed executives who were passed over for the CEO role ("succession losers") and their subsequent careers. It found that 74% of passed over executives left their companies, with 30% eventually becoming CEOs elsewhere. However, companies led by succession losers saw average stock price declines of 13% over 3 years, compared to gains for companies whose CEO selections remained unchanged. The findings suggest that boards generally identify the most qualified CEO candidates, though differences between internal and external hires complicate comparisons.
Merck announced third quarter 2003 earnings per share of $0.83, a 6% increase over 2002. Net income was $1.865 billion. Merck will reduce costs by eliminating 4,400 positions and implementing a new U.S. wholesaler distribution program. As a result of these actions, full year 2003 EPS is expected to be $2.90 to $2.95. Major products like Zocor, Fosamax, Cozaar, and Singulair saw sales increases, but did not meet targets. Merck completed the spin-off of Medco and increased ownership of Banyu to 99%.
Merck announced its earnings per share guidance for 2005 of $2.42 to $2.52 per share, anticipating continued growth of newer products like ZETIA and VYTORIN. It also reaffirmed its 2004 EPS guidance of $2.59 to $2.64 per share, despite a $0.50 to $0.55 per share negative impact from withdrawing VIOXX. Merck expects to file several vaccine candidates and a new diabetes drug in 2005 and continue stock buybacks while growing sales of major products like ZOCOR, FOSAMAX, COZAAR/HYZAAR, and SINGULAIR.
- Merck reported first quarter 2005 earnings per share of $0.62, down from $0.73 in the first quarter of 2004. However, sales of newer products grew and cost management led expenses to be lower than expected.
- For 2005, Merck anticipates EPS between $2.44-$2.52 and second quarter EPS of $0.60-$0.64. Several new product approvals and indications were announced in the first quarter.
- Merck's major product franchises like Singulair, Cozaar, Fosamax, and Zocor remain top sellers. Late-stage vaccines and other pipeline candidates are progressing on schedule.
Merck reported double-digit revenue and earnings-per-share growth for Q3 2007. Revenue grew 12% to $6.1 billion driven by strong sales of key products like SINGULAIR, JANUVIA, GARDASIL and VARIVAX. EPS for Q3 2007 was $0.75 excluding restructuring charges. Merck also gained FDA approval for its HIV treatment ISENTRESS and raised full-year 2007 EPS guidance to a range of $3.08 to $3.14 excluding restructuring charges.
Merck announced strong financial results for full-year and fourth-quarter 2005. Full-year earnings per share were $2.53 including a $295 million reserve for VIOXX legal defense costs, while reported EPS were $2.10. Fourth-quarter EPS were $0.64 including the VIOXX reserve. Merck reaffirmed its 2006 EPS guidance range despite eliminating 1,100 positions through a global restructuring involving site closures. Key products like Singulair and the cholesterol franchise performed well.
Merck has undergone several strategic changes over the last 10 years driven by external factors. Competitive pressures from other major pharmaceutical companies like Pfizer and GlaxoSmithKline prompted Merck to pursue acquisitions and diversify into new business areas. Regulations from government agencies also impacted Merck's marketing strategies and product liability costs. Economic conditions negatively affected revenue, requiring cost cutting measures and layoffs. Merck adapted by shifting research focus, pursuing partnerships and licenses, and targeting emerging international markets through acquisitions and new facilities.
Merck reported strong financial results for the first quarter of 2007. Worldwide sales increased 7% compared to the first quarter of 2006. Key products such as SINGULAIR, vaccines including GARDASIL, and the cholesterol drugs ZETIA and VYTORIN drove company growth. Merck anticipates second quarter EPS between $0.67-$0.71 and reaffirmed its full-year 2007 EPS guidance range.
Merck Serono will partner with Lupin Limited to expand its general medicines portfolio in emerging markets. Through this partnership, Merck Serono will add up to 20 new affordable, high-quality products focused on cardiovascular and diabetes diseases in countries in Latin America, Asia, Central Eastern Europe, and Africa. Lupin will provide product dossiers and finished product supply to support the portfolio expansion. The first launches under the partnership are expected in 2016, allowing Merck Serono to better address local healthcare needs in fast-growing regions.
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...IMARC Group
The global infantile spasms therapeutics market size reached US$ 3.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 4.2% during 2023-2028.
More Info:- https://www.imarcgroup.com/infantile-spasms-therapeutics-market
Merck announced its 2006 financial results, reporting solid revenue growth. Key points:
- Vaccines, SINGULAIR, ZETIA and VYTORIN drove full-year revenue increases. Launches of GARDASIL and JANUVIA provide a platform for continued growth in 2007.
- Full-year 2006 earnings per share were $2.52 excluding certain charges, and $2.03 as reported. Fourth-quarter earnings per share were $0.50 and $0.22, respectively.
- Merck reaffirmed its guidance for 2007 earnings per share between $2.51-$2.59 excluding charges, and $2.36-$2.49 as reported.
Cholera Vaccines Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and ...IMARC Group
The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032.
More Info:- https://www.imarcgroup.com/cholera-vaccines-market
Merck Paper Securities and Protfolio AnalysisJason Sandoy
Merck & Co. is a large pharmaceutical company that produces many drugs across different medical fields. The report recommends buying Merck stock based on its large drug pipeline, cost savings initiatives, and undervaluation relative to estimates. Merck allocates billions to research and development each year to develop new drugs and maintain a diverse portfolio to drive future growth. While some ratios show Merck lagging competitors, its growth rates exceed industry averages, and initiatives to reduce costs are expected to increase returns. Overall the report finds Merck positioned for continued growth and profitability.
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)Steven Sabo
The document is a letter of transmittal from a team of students to their professors submitting a report analyzing the global pharmaceutical companies Merck & Co. and Sanofi. The team's analysis identified three key success factors for companies in the industry and concluded that based on these factors, Sanofi is currently in a better position than Merck & Co. to succeed. The letter requests feedback from the professors and offers to further discuss the report and its analyses and recommendations.
This document provides a business plan for a new pharmaceutical company called NEWTech Advant. The plan includes a situation analysis of the pharmaceutical market, noting trends like an aging population and increased regulation. It outlines NEWTech Advant's goals of improving existing drugs and discovering new ones. The marketing strategy discusses targeting physicians and patients aged 45+, and increasing market share through advertising. Financial objectives include achieving profitability in three years. The plan also analyzes strengths, weaknesses, opportunities and threats for the new company.
The global vaccine delivery devices market size reached US$ 7.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.9 Billion by 2028, exhibiting a growth rate (CAGR) of 7.5% during 2023-2028.
More info:- https://www.imarcgroup.com/vaccine-delivery-devices-market
The document analyzes the global pharmaceutical industry, identifying the United States and France as the largest markets. It outlines three key success factors for companies in the industry: having products in fast-growing therapeutic classes like oncology and diabetes; involvement in emerging biotechnology; and managing patent expirations. The document then evaluates Merck & Co. and Sanofi based on these three success factors.
Immunotherapy Drugs Market PPT: Demand, Trends and Business Opportunities 202...IMARC Group
The global immunotherapy drugs market size reached US$ 195.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 327.8 Billion by 2028, exhibiting a growth rate (CAGR) of 8.9% during 2023-2028.
More Info:- https://www.imarcgroup.com/immunotherapy-drugs-market
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies that require long-term treatment. This allows companies to build more stable customer bases. The document also outlines some of the challenges companies face, such as increased competition, high costs of research and development, and complex decision-making processes involving doctors, patients, and other stakeholders. It discusses two common business models - the "super core model" involving a small number of highly successful chronic drugs, and the "core model" involving marketing a larger number of acute drugs.
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies. This represents a long-term strategy change as chronic therapies require doctors to prescribe the same drugs for longer periods. The document also outlines some of the challenges pharmaceutical companies face in marketing to different customers in the supply chain from doctors to patients. It discusses strategies around patents, research and development, and pursuing either a "super core" model focused on a small number of chronic drugs or a "core" model marketing more acute drugs.
Biopharmaceuticals product segments analyzed in this study comprises Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and others. Therapeutic areas analyzed include Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and others. Biopharmaceuticals market, estimated at US$199.7 billion globally in 2013, is further projected to reach US$497.9 billion by 2020, growing at 13.5% CAGR between 2010 and 2020. Among different product segments, monoclonal antibodies (moAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US$51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US$56.3 billion, and further expected reach a projected US$144.5 billion by 2020.
This document contains slides from an American Airlines presentation given by Gerard Arpey, Chairman & CEO. It discusses several topics:
1) Safe harbor statements noting forward-looking statements are subject to risk factors.
2) Rising oil prices, showing a graph of prices rising from $58 in 2007 to over $134 in mid-2008, offsetting the company's $6 billion in cost reductions.
3) New baggage and change fees announced to offset rising fuel costs, expected to generate several hundred million dollars.
This document contains a presentation by Beverly Goulet, Vice President of Corporate Development and Treasurer of an unnamed company, covering various topics:
1) It includes statements regarding forward-looking comments being subject to risk factors that could affect actual results.
2) Slide 3 discusses the company's fuel hedging for 3Q08 and full year 2008.
3) Slide 20 shows the company's net debt levels from 2002-2008, which have increased significantly.
The presentation provides an overview of the company's financial performance, fuel costs and hedging, debt levels, and other key metrics.
Credit Suisse Group Global Airline Conference Presentationfinance11
This document contains a presentation by Beverly Goulet, Vice President of Corporate Development and Treasurer of an unnamed company. The presentation includes slides on the company's 3Q08 results showing a net loss compared to earnings in the prior year. Additional slides provide details on oil prices, the company's hedging strategy, total debt levels, planned 2009 capacity reductions, new and modified fees, investments in the future, and alliances. The presentation contains forward-looking statements and refers readers to SEC filings and a webcast for further information.
- The document is a letter informing stockholders about AMR Corporation's 2004 Annual Meeting of Stockholders to be held on May 19, 2004 at the American Airlines Training & Conference Center in Fort Worth, Texas.
- Stockholders are invited to attend and vote on items of business including electing 12 directors, ratifying the selection of Ernst & Young LLP as independent auditors, and considering two stockholder proposals.
- Instructions are provided for stockholders on how to vote, including voting online, by telephone, or by returning a proxy card, and details on admission to the annual meeting by ticket.
The document is a notice from AMR Corporation inviting stockholders to attend its 2005 Annual Meeting of Stockholders on May 18, 2005 at 8:00am at the American Airlines Training & Conference Center in Fort Worth, Texas. It provides information on the items of business to be voted on, including the election of directors, ratification of auditors, and a stockholder proposal. Stockholders of record as of March 21, 2005 are entitled to vote. Admission to the meeting will require an admission ticket or proof of stock ownership.
The document is a notice from AMR Corporation inviting shareholders to attend its 2006 Annual Meeting of Stockholders on May 17, 2006. It provides information on voting procedures and requirements for attendance. Shareholders as of March 20, 2006 are entitled to vote. The meeting will be held at the American Airlines Training & Conference Center in Fort Worth, Texas, where admission will require a ticket or proof of stock ownership.
AMR 2006 Shareholders’ Meeting Voting Resultsfinance11
All 13 nominees for Director were elected at American Airlines' 2006 stockholders meeting on May 17, 2006. Over 93% of shares were voted, with 176 million shares represented. Ernst & Young was ratified as the independent auditor with over 99% of votes in favor. Proposals relating to term limits for outside directors, majority vote requirements, separation of CEO/Chairman roles, and cumulative voting all failed to pass, receiving only around 30% support or less.
The document is a letter inviting stockholders to attend AMR Corporation's annual meeting on May 16, 2007. It provides details on the meeting location, eligibility to vote, and how to submit a proxy vote by internet, phone, or mail. Stockholders are encouraged to vote as their input is important. Management will provide updates and answer questions at the meeting.
AMR 2007 Shareholders’ Meeting Voting Resultsfinance11
At the American Airlines 2007 stockholders meeting on May 16, 2007:
- All 12 nominees for the board of directors were elected, with over 90% of shares voted.
- Stockholders ratified the selection of Ernst & Young LLP as independent auditors for 2007 with over 98% of votes for.
- Stockholder proposals relating to cumulative voting, special shareholder meetings, performance based stock options, and advisory resolution to ratify executive compensation all failed to pass, receiving less than 55% of votes.
The document is a notice for the annual stockholder meeting of AMR Corporation to be held on May 21, 2008. It provides details on the meeting such as time, location, items of business to be addressed which include electing directors, ratifying auditors, and considering four stockholder proposals. It also covers eligibility to attend, requirements to vote, and quorum details. Stockholders are encouraged to vote by proxy in advance of the meeting.
AMR 2008 Shareholders’ Meeting Voting Resultsfinance11
1. All 13 nominees for Director were elected at the 2008 Stockholders Meeting with a minimum of 181,494,763 votes for.
2. The ratification of Ernst & Young LLP as independent auditors for 2008 was approved with 98.45% of votes for and 1.55% against.
3. A stockholder proposal relating to cumulative voting for election of directors was rejected with 30.80% of votes for and 69.20% against.
AMR Corporation had a very successful 1998 financially. The company reported record net earnings of $1.3 billion, a 33.4% increase over 1997. AMR's strong performance was driven by robust demand for air travel and lower fuel prices, enabling the airline businesses to increase revenues without significant fare discounting. AMR also made progress across its key strategic objectives - growing its airline networks, improving customer service, and expanding The Sabre Group's technology solutions business.
This document is the annual report for AMR Corporation for the year 2000. It discusses the company's improved financial performance for the year, including net earnings of $752 million compared to $543 million in 1999. It summarizes strategic initiatives undertaken in 2000 related to safety, service, product, technology, culture, and network - the six areas of the company's Airline Leadership Plan. These initiatives include fleet expansion, onboard comfort enhancements, technology investments, employee programs, and network growth through regional jets and international partnerships. The report also outlines major acquisitions announced in 2001 that will significantly expand American Airlines' fleet and network by acquiring assets from TWA, US Airways, and a stake in DC Air.
The document discusses the challenges American Airlines faced in 2001, including a slowing economy before September 11th and the devastating impacts of the terrorist attacks on September 11th and the loss of Flight 587 in November. It describes the cost-cutting measures American took, such as reducing capacity, retiring aircraft, cutting capital and operating expenses. It highlights that despite the difficulties, American completed the acquisition and integration of TWA and continued its More Room Throughout Coach campaign. The letter closes by stating that while 2001 brought great challenges, American's values and principles will guide it going forward.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
5 Tips for Creating Standard Financial ReportsEasyReports
Well-crafted financial reports serve as vital tools for decision-making and transparency within an organization. By following the undermentioned tips, you can create standardized financial reports that effectively communicate your company's financial health and performance to stakeholders.
[4:55 p.m.] Bryan Oates
OJPs are becoming a critical resource for policy-makers and researchers who study the labour market. LMIC continues to work with Vicinity Jobs’ data on OJPs, which can be explored in our Canadian Job Trends Dashboard. Valuable insights have been gained through our analysis of OJP data, including LMIC research lead
Suzanne Spiteri’s recent report on improving the quality and accessibility of job postings to reduce employment barriers for neurodivergent people.
Decoding job postings: Improving accessibility for neurodivergent job seekers
Improving the quality and accessibility of job postings is one way to reduce employment barriers for neurodivergent people.
Understanding how timely GST payments influence a lender's decision to approve loans, this topic explores the correlation between GST compliance and creditworthiness. It highlights how consistent GST payments can enhance a business's financial credibility, potentially leading to higher chances of loan approval.
Independent Study - College of Wooster Research (2023-2024) FDI, Culture, Glo...AntoniaOwensDetwiler
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
How Does CRISIL Evaluate Lenders in India for Credit RatingsShaheen Kumar
CRISIL evaluates lenders in India by analyzing financial performance, loan portfolio quality, risk management practices, capital adequacy, market position, and adherence to regulatory requirements. This comprehensive assessment ensures a thorough evaluation of creditworthiness and financial strength. Each criterion is meticulously examined to provide credible and reliable ratings.
Vicinity Jobs’ data includes more than three million 2023 OJPs and thousands of skills. Most skills appear in less than 0.02% of job postings, so most postings rely on a small subset of commonly used terms, like teamwork.
Laura Adkins-Hackett, Economist, LMIC, and Sukriti Trehan, Data Scientist, LMIC, presented their research exploring trends in the skills listed in OJPs to develop a deeper understanding of in-demand skills. This research project uses pointwise mutual information and other methods to extract more information about common skills from the relationships between skills, occupations and regions.
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby...Donc Test
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting, 8th Canadian Edition by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Ebook Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Pdf Solution Manual For Financial Accounting 8th Canadian Edition Pdf Download Stuvia Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Financial Accounting 8th Canadian Edition Ebook Download Stuvia Financial Accounting 8th Canadian Edition Pdf Financial Accounting 8th Canadian Edition Pdf Download Stuvia
BONKMILLON Unleashes Its Bonkers Potential on Solana.pdfcoingabbar
Introducing BONKMILLON - The Most Bonkers Meme Coin Yet
Let's be real for a second – the world of meme coins can feel like a bit of a circus at times. Every other day, there's a new token promising to take you "to the moon" or offering some groundbreaking utility that'll change the game forever. But how many of them actually deliver on that hype?
Seminar: Gender Board Diversity through Ownership NetworksGRAPE
Seminar on gender diversity spillovers through ownership networks at FAME|GRAPE. Presenting novel research. Studies in economics and management using econometrics methods.
1. News Release
_____________________________________________________________________________________________
Media Contacts: Tony Plohoros Investor Contact: Mark Stejbach
(908) 423-3644 (908) 423-5185
Anita Larsen
(908) 423-6022
Merck Announces Second-Quarter 2004 Earnings Per Share (EPS) of 79 Cents
• Merck Reaffirms Full-Year 2004 EPS Guidance of $3.11 to $3.17
• Merck Anticipates Third-Quarter EPS of 80 to 84 Cents
• Diabetes Compound MK-431 Enters Phase III Clinical Trials
• Merck and Bristol-Myers Squibb Enter Global Development and
Commercialization Alliance for Muraglitazar, a Novel Compound for Treatment
of Diabetes
• Merck and Vertex Enter Broad Collaboration to Develop and Commercialize
VX-680, a Novel Compound for the Treatment of Cancer
• Merck and H. Lundbeck A/S Extend Agreement for the Exclusive Development
and Commercialization of Sleep Disorder Compound Gaboxadol to Japan
WHITEHOUSE STATION, N.J., July 21, 2004 – Merck & Co., Inc. today announced that
earnings per share for the second quarter of 2004 were $0.79, level with earnings per share
from continuing operations* during the same period in 2003. Net income was $1,768.1 million,
compared to income from continuing operations of $1,784.5 million in the second quarter of last
year. Worldwide sales grew 9% to $6.0 billion for the quarter.
For the first six months of 2004, earnings per share were $1.52, compared to earnings
per share from continuing operations of $1.47 during the first six months of 2003. Net income
was $3,386.7 million, compared to income from continuing operations of $3,329.4 million for the
first six months of 2003. Sales grew 5% for the period to $11.7 billion.
“Our strategic investments in our pipeline continue to strengthen Merck’s prospects for
both near- and long-term growth,” said Merck Chairman, President and Chief Executive Officer
Raymond V. Gilmartin.
Sales growth of Merck’s major in-line franchises collectively was offset by lower
revenues from Merck’s relationship with AstraZeneca LP, which were primarily driven by generic
and over-the-counter competition. Overall, second-quarter sales performance included a
- more -
*Continuing operations exclude only the results from Medco Health Solutions, Inc., which was spun off on Aug. 19, 2003.
2. 2
3-point favorable effect from foreign exchange. Sales outside of the United States accounted
for 43% of second-quarter sales, compared to 42% of sales for the second quarter of 2003.
Sales growth for the quarter includes a favorable comparison to 2003, which was
impacted by $405 million of wholesaler buy-out. Following the implementation of the new
distribution program for U.S. wholesalers in the fourth quarter of 2003, fluctuations in 2004 sales
caused by wholesaler investment buying have significantly moderated.
Marketing and administrative expenses increased 2% compared to the second quarter of
2003. Excluding the impact of $21 million for restructuring costs related to position eliminations,
marketing and administrative expenses for the second quarter were at the same level as 2003.
The company is on track to eliminate 4,400 positions worldwide. Approximately 4,000 positions
had been eliminated as of June 30. This program, which was announced in October 2003, will
be completed by the end of 2004.
Third-Quarter and Full-Year 2004 EPS Guidance
Merck anticipates third-quarter earnings per share (EPS) of $0.80 to $0.84. Merck
reaffirms full-year 2004 EPS of $3.11 to $3.17. Please see pages 9-10 of this news release for
a breakdown of Merck’s full-year 2004 financial guidance.
Continued Strong Growth in Strategic Licensing Activities
Merck continued to augment its internal research efforts with a comprehensive licensing
and external alliance strategy across the entire spectrum of collaborations from early research
to late-stage compounds, as well as new technologies and targeted acquisitions. In the first half
of 2004, Merck executed 26 significant transactions, including research collaborations, pre-
clinical and clinical compounds and technology transactions, and has more than 40
opportunities currently in detailed review. Since the beginning of 2002, Merck has entered into
more than 110 such transactions.
Research and development expenses increased 25% during the second quarter,
including the impact of Merck’s external collaborations, such as with Bristol-Myers Squibb and
Vertex Pharmaceuticals.
In April, Merck and Bristol-Myers Squibb entered into a global collaborative agreement
for muraglitazar, Bristol-Myers Squibb’s dual PPAR (peroxisome proliferator-activated receptor)
agonist, currently in Phase III clinical development for use in treating both blood glucose and
lipid abnormalities in patients with type 2 diabetes. Bristol-Myers Squibb received a $100 million
- more -
3. 3
upfront payment and could receive additional milestone payments. Merck and Bristol-Myers
Squibb will jointly develop the clinical and marketing strategy for muraglitazar and share equally
in future development and commercialization costs. Both companies will co-promote the
product to physicians on a global basis, and Merck will receive payments based on net sales
levels.
In June, Merck and Vertex Pharmaceuticals Incorporated entered into a global
collaboration to develop and commercialize VX-680, Vertex’s lead Aurora kinase inhibitor that is
expected to enter clinical development this year for the treatment of cancer. Aurora kinases are
implicated in the onset and progression of many different human cancers, and novel Aurora
kinase inhibitors such as VX-680 have the potential to play an important future role in the
treatment and management of a wide range of tumor types. Vertex received a $20 million
upfront payment and could receive up to an additional $14 million in research funding over the
next two years. In addition, Vertex could receive additional milestone payments.
Also in June, Merck and H. Lundbeck A/S announced an extension of their agreement
for the exclusive development and commercialization of the sleep disorder compound
gaboxadol to Japan. In February, the two companies announced their alliance for the exclusive
U.S. development and commercialization of gaboxadol. Under the terms of the extended
agreement, Merck and Lundbeck will jointly conduct the clinical program required for filing a
New Drug Application (NDA) in Japan, with Merck funding the majority of the development
activities. Following approval, the companies plan to co-promote gaboxadol in Japan.
Lundbeck will receive a share of Japanese gaboxadol sales.
Merck Late-Stage Pipeline Shows Promise
As expected, Merck’s investigational compound, MK-431, a DP-IV inhibitor for the
treatment of type 2 diabetes, entered Phase III clinical trials during the second quarter. The
company anticipates filing for regulatory approval in 2006.
Merck’s investigational pentavalent rotavirus vaccine, ROTATEQ, demonstrated 100-
percent efficacy against severe rotavirus gastroenteritis and 74-percent efficacy against
rotavirus gastroenteritis of any severity in healthy infants, according to results from a new dose-
ranging study presented at the annual meeting of the European Society for Pediatric Infectious
Diseases in May. Merck is currently conducting the large-scale Rotavirus Efficacy and Safety
Trial (REST) with more than 65,000 infants at clinical sites around the world, which will provide
additional safety and efficacy data. The company expects to submit a Product License
- more -
4. 4
Application (PLA) to the U.S. Food & Drug Administration (FDA) for ROTATEQ in the second
half of 2005. In children under 5, rotavirus causes approximately one-third of diarrhea-
associated hospitalizations in developing countries and nearly half a million deaths worldwide
every year.
In a new study presented at the National Immunization Conference, a single dose of
PROQUAD in 4- to 6-year-olds used in place of the routinely administered second dose of
M-M-R II was generally well-tolerated and resulted in antibody responses similar to those
developed with M-M-R II and VARIVAX separately. PROQUAD is Merck’s investigational
vaccine that adds the chickenpox vaccine to Merck’s existing measles, mumps and rubella
vaccine. The company expects to submit a PLA to the FDA for PROQUAD in the second half of
2004.
Major In-Line Product Performance
Each of Merck’s major in-line franchises ranks either No. 1 or 2 in its class, in terms of
worldwide sales, as Merck continues to demonstrate the value of its medicines to patients,
physicians and payers through proven health outcomes.
Worldwide sales of ZOCOR, Merck’s statin for modifying cholesterol, reached $1.4
billion in the second quarter and $2.7 billion for the first six months. U.S. mail-order-adjusted
prescription levels for ZOCOR increased by approximately 3 percent for the quarter, as
compared to the second quarter of 2003. Merck continues to communicate the results of the
landmark Heart Protection Study (HPS) to physicians and consumers.
In July, the National Cholesterol Education Program (NCEP) issued a report
recommending modifications to the Adult Treatment Panel III (ATP III) guidelines. The report,
which was based on five major studies, including HPS, was endorsed by: the American Heart
Association; the American College of Cardiology; and the National Heart, Lung, and Blood
Institute. The new report may lead to an increase in the number of people for whom
cholesterol-lowering medicines should be considered. Under the NCEP ATP III guidelines, an
estimated 36 million people would be eligible for cholesterol-lowering medication such as
ZOCOR for cholesterol management. According to the new report, in high-risk persons, the
recommended LDL-C goal is < 100 mg/dL. The report also indicates that when risk is very high,
such as for a patient with established cardiovascular disease plus multiple major risk factors
(especially diabetes), an LDL-C goal of < 70 mg/dL is a reasonable clinical strategy for
physicians.
- more -
5. 5
FOSAMAX continued as the most-prescribed medicine worldwide for the treatment of
postmenopausal, male and glucocorticoid-induced osteoporosis. Global sales were strong,
reaching $792 million during the quarter and $1.6 billion for the first six months. U.S. mail-
order-adjusted prescription levels for FOSAMAX were in line with second-quarter 2003 levels.
In April, the Journal of Internal Medicine published findings from the first international
head-to-head study that compared the efficacy of FOSAMAX Once Weekly (alendronate) 70 mg
to Evista (raloxifene) 60 mg once daily, which showed that FOSAMAX provided significantly
greater increases in bone mineral density at the lumbar spine and total hip.
The potential for continued growth in the osteoporosis market remains strong worldwide.
Fewer than 25 percent of women with osteoporosis in seven major markets (the United States,
Canada, the United Kingdom, France, Italy, Germany and Spain) have been diagnosed and
treated. In the United States, market research suggests that fewer than 40 percent of women
who have had a bone mineral density test – and have been told by their doctors they have
osteoporosis or osteopenia – receive treatment.
Global sales of Merck’s antihypertensive medicines, COZAAR and HYZAAR**, were
strong, reaching $725 million for the quarter and $1.4 billion for the first six months. COZAAR
and HYZAAR compete in the fastest-growing class in the antihypertensive market, angiotensin
II antagonists (AIIA). COZAAR is the second-most-frequently prescribed AIIA in the United
States and the largest-selling AIIA in Europe. U.S. mail-order-adjusted prescription levels for
COZAAR and HYZAAR increased by 5 percent during the quarter, as compared to the second
quarter of 2003.
Worldwide sales of SINGULAIR, a once-a-day oral medicine indicated for the treatment
of chronic asthma and the relief of symptoms of seasonal allergic rhinitis, were strong, reaching
$643 million in the second quarter and $1.3 billion during the first six months. U.S. mail-order-
adjusted prescription levels for SINGULAIR increased by 21 percent during the quarter, as
compared to the second quarter of 2003. SINGULAIR continues to be the second-most-
prescribed product in the overall respiratory market in the United States as patients, physicians
and managed care organizations continue to recognize the value SINGULAIR offers to those
who suffer from asthma or seasonal allergic rhinitis.
Worldwide sales of VIOXX, Merck’s arthritis and pain medicine, were $653 million for the
second quarter and $1.3 billion for the first six months. U.S. mail-order-adjusted prescription
levels for VIOXX decreased by 5 percent during the quarter, as compared to the second quarter
of 2003.
- more -
**COZAAR and HYZAAR are registered trademarks of E.I. DuPont de Nemours & Company, Wilmington, Del.
6. 6
Following FDA approval for the acute treatment of migraine in late March, VIOXX is now
approved for treating more types of painful conditions than any other coxib in the United States
and remains the only coxib approved to relieve migraine pain and associated migraine
symptoms. Merck continues to seek new uses for VIOXX to extend the clinical benefits of the
product to new populations. A supplemental NDA for VIOXX is under review by the FDA for the
treatment of juvenile rheumatoid arthritis.
Outside of the United States, VIOXX continues to be the best-selling arthritis and pain
medicine. Indications for VIOXX for migraine and juvenile rheumatoid arthritis also are being
sought outside of the United States.
Global sales of Merck’s newest coxib, ARCOXIA, reached $62 million in the second
quarter and $92 million for the first six months. To date, ARCOXIA has been launched in 45
countries outside of the United States. Additional launches will continue in other countries
throughout the year.
During the second quarter, the FDA informed Merck that there are no plans for an
Advisory Committee meeting for ARCOXIA at this time. Under PDUFA (Prescription Drug User
Fee Act), for standard NDAs filed in 2003, FDA’s goal is to review and act on 90 percent of
NDAs within 10 months of filing. The goal PDUFA date for the NDA for ARCOXIA is Oct. 30,
2004.
Results from two acute dental pain studies with ARCOXIA were published during the
second quarter. The first study, published in Clinical Therapeutics, showed that patients taking
ARCOXIA 120 mg experienced pain relief lasting for a full 24 hours compared with 10 hours for
patients taking ibuprofen. In the second study, published in the Clinical Journal of Pain, patients
taking ARCOXIA 120 mg or naproxen sodium 550 mg had significantly greater pain relief scores
over eight hours than those taking a commonly used narcotic, acetaminophen with codeine.
Sales of Merck’s other promoted medicines and vaccines were $1.3 billion during the
second quarter and $2.5 billion for the first six months. Sales of these products were $1.2 billion
and $2.4 billion, respectively, during the same periods last year. These products treat or
prevent a broad range of conditions, such as infectious disease, glaucoma, benign prostate
enlargement and migraine.
Global sales of ZETIA (branded EZETROL outside of the United States), the cholesterol
absorption inhibitor developed and marketed by Merck and Schering-Plough, reached $242
million in the second quarter and $432 million for the first six months. More than 9.6 million
prescriptions have been written in the United States since the U.S. launch of ZETIA in mid-
- more -
7. 7
November 2002, according to IMS Health. ZETIA currently accounts for 6 percent of new
prescriptions in the cholesterol-lowering class and is now reimbursed for nearly 90 percent of all
patients in managed care plans across the United States. To date, EZETROL has been
launched in more than 40 countries outside of the United States. Additional markets are
expected to launch EZETROL in 2004 upon completion of pricing/reimbursement national
processes.
VYTORIN (branded INEGY in many countries outside of the United States) has been
recently launched in Germany and Mexico. Additional markets are expected to launch
VYTORIN in 2004 upon completion of pricing/reimbursement national processes. VYTORIN is
the first product to target the body’s two sources of cholesterol through dual inhibition –
inhibiting both cholesterol production in the liver and absorption in the intestine.
Merck/Schering-Plough Pharmaceuticals submitted an NDA for VYTORIN to the FDA on Sept.
24, 2003. The filing was accepted by the FDA for standard review on Nov. 23, 2003.
Additional Second-Quarter Activities
On July 6, the United States District Court for the District of New Jersey granted a
motion by Merck, Medco Health Solutions and certain officers and directors to dismiss a
purported class action complaint. The case involves claims related to Merck’s revenue
recognition practice for retail co-payments paid by individuals to whom Medco Health Solutions
provides pharmaceutical benefits, as well as other allegations. The complaint was dismissed
with prejudice. The Court’s decision is subject to appeal. Merck is awaiting decision on a
motion before the same Court to dismiss a related shareholder derivative action.
In order to ensure there are no reporting relationships among members of Merck’s Board
of Directors, William Daley and Heidi Miller recently resigned from the Merck Board. Mr. Daley
has assumed a position with JP Morgan Chase, where Merck Board member William B.
Harrison, Jr. is chairman and chief executive officer. Ms. Miller, who was an employee of Bank
One prior to its merger with JP Morgan Chase, assumed a position with JP Morgan Chase after
the merger.
Earnings Conference Call
Investors are invited to a live Web cast of Merck’s second-quarter earnings conference
call today at 9 a.m. ET, by visiting the Newsroom section of Merck’s Web site
(www.merck.com/newsroom). Institutional investors and analysts can participate in the call by
- more -
8. 8
dialing (913) 981-4910. Journalists are invited to listen by dialing (913) 981-5522. The Web
cast will be available for replay on the Web site until July 28.
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical products company. Merck
discovers, develops, manufactures and markets a broad range of innovative products to
improve human and animal health, directly and through its joint ventures.
Forward-Looking Statement
This press release, including the financial information that follows, contains “forward-
looking statements” as that term is defined in the Private Securities Litigation Reform Act of
1995. These statements involve risks and uncertainties, which may cause results to differ
materially from those set forth in the statements. The forward-looking statements may include
statements regarding product development, product potential or financial performance. No
forward-looking statement can be guaranteed, and actual results may differ materially from
those projected. Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise. Forward-looking
statements in this press release should be evaluated together with the many uncertainties that
affect Merck’s business, particularly those mentioned in the cautionary statements in Item 1 of
Merck’s Form 10-K for the year ended Dec. 31, 2003, and in its periodic reports on Form 10-Q
and Form 8-K (if any) which the company incorporates by reference.
###
9. 9
Merck Financial Guidance for 2004
Worldwide net sales will be driven by the company's major in-line products, including the impact
of new studies and indications. Sales forecasts for those products for 2004 are as follows:
WORLDWIDE
PRODUCT THERAPEUTIC CATEGORY 2004 NET SALES
ZOCOR Cholesterol modifying $4.9 to $5.1 billion
FOSAMAX Osteoporosis $3.0 to $3.2 billion
COZAAR / HYZAAR Hypertension $2.7 to $2.9 billion
Coxibs Arthritis and Pain $2.8 to $3.0 billion
(VIOXX and ARCOXIA)
SINGULAIR Asthma and Seasonal Allergic Rhinitis $2.4 to $2.7 billion
• Under an agreement with AstraZeneca (AZN), Merck receives revenue at predetermined rates
on the U.S. sales of certain products by AZN, most notably PRILOSEC and NEXIUM. In 2004,
Merck anticipates these revenues to be approximately $1.5 to $1.7 billion.
• The income contribution related to the Merck and Schering-Plough collaboration is expected
to be positive in 2004. Equity Income from Affiliates includes the results of the Merck and
Schering-Plough collaboration combined with the results of Merck’s other joint venture
relationships. Equity Income from Affiliates is expected to be approximately $850 to $950
million for 2004.
• Merck continues to expect that manufacturing productivity will offset inflation on product
costs.
• Product gross margin percentage is estimated to be approximately 80 to 81 percent as a
result of changes to the sales mix.
• Research and Development expense (which excludes joint ventures) is anticipated to
increase at a high-teens percentage growth rate over the full-year 2003 level. This guidance
includes acquired R&D expenses in 2003 and 2004.
• Consolidated Marketing and Administrative expense is estimated to be at the same level as
the full-year 2003 expense. This guidance excludes restructuring costs in 2003 and 2004.
• The consolidated 2004 tax rate is estimated to be approximately 28 to 29 percent.
• Merck plans to continue its stock buyback program in 2004. As of June 30, $9.1 billion
remains under the current buyback authorizations approved by Merck’s Board of Directors.
The company is on track to eliminate 4,400 positions worldwide. Approximately 4,000
positions had been eliminated as of June 30. This program, which was announced in October
2003, will be completed by the end of 2004. Restructuring costs for full-year 2004 are expected
to be approximately $60 to $80 million.
Given these guidance elements, and including the effect of the restructuring, Merck & Co.,
Inc. anticipates full-year 2004 earnings per share (EPS) of $3.11 to $3.17 and third-quarter EPS of
$0.80 to $0.84.
- more -
10. 10
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical products company. Merck
discovers, develops, manufactures and markets a broad range of innovative products to
improve human and animal health, directly and through its joint ventures.
Forward-Looking Statement
This press release contains “forward-looking statements” as that term is defined in the
Private Securities Litigation Reform Act of 1995. These statements involve risks and
uncertainties, which may cause results to differ materially from those set forth in the statements.
The forward-looking statements may include statements regarding product development,
product potential or financial performance. No forward-looking statement can be guaranteed,
and actual results may differ materially from those projected. Merck undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new information, future
events, or otherwise. Forward-looking statements in this press release should be evaluated
together with the many uncertainties that
affect Merck’s business, particularly those mentioned in the cautionary statements in Item 1 of
Merck’s Form 10-K for the year ended Dec. 31, 2003, and in its periodic reports on Form 10-Q
and Form 8-K (if any) which the company incorporates by reference.
###
11. 11
The following tables show the financial results for Merck & Co., Inc. and subsidiaries for the
quarter and six months ended June 30, 2004, compared with the corresponding period of the
prior year.
Merck & Co., Inc.
Consolidated Results
(In Millions Except Earnings per Common Share)
Quarter Ended June 30
%
2004 2003 Change
Sales $6,021.7 $5,525.4 9%
Costs, Expenses and Other
Materials and production 1,131.3 988.5 14
Marketing and administrative (1) 1,616.2 1,589.9 2
Research and development (2) 986.0 786.4 25
Equity income from affiliates (220.5) (187.4) 18
Other (income) expense, net 69.9 (121.8) *
Income from Continuing Operations
Before Taxes 2,438.8 2,469.8 -1
Taxes on Income (3) 670.7 685.3
Income from Continuing Operations $1,768.1 $1,784.5 -1
Income from Discontinued Operations, Net of
Taxes -- 82.5
Net Income $1,768.1 $1,867.0 N/M
Average Shares Outstanding
Assuming Dilution 2,230.1 2,261.1
Earnings per Common Share
Assuming Dilution
Continuing Operations $0.79 $0.79 --
Discontinued Operations -- 0.04
Total $0.79 $0.83 N/M
N/M Comparison not meaningful as a result of the spin-off of Medco Health.
* > 100%
(1) 2004 Marketing and administrative expense includes $21 million for restructuring costs.
(2) Research and development expense includes licensing expense for research collaborations, including
the initial payments of $100 million to Bristol-Myers Squibb and $20 million to Vertex in the second quarter
of 2004.
(3) The effective tax rate was 27.5% and 27.7% for the second quarter of 2004 and 2003, respectively.
12. 12
Merck & Co., Inc.
Consolidated Results
(In Millions Except Earnings per Common Share)
Six Months Ended June 30
%
2004 2003 Change
Sales $11,652.6 $11,096.8 5%
Costs, Expenses and Other
Materials and production 2,247.1 2,068.6 9
Marketing and administrative (1) 3,227.6 3,103.9 4
Research and development (2) 1,982.3 1,597.1 24
Equity income from affiliates (415.2) (284.7) 46
Other (income) expense, net (170.9) (74.0) *
Income from Continuing Operations
Before Taxes 4,781.7 4,685.9 2
Taxes on Income (3) 1,395.0 1,356.5
Income from Continuing Operations $3,386.7 $3,329.4 2
Income from Discontinued Operations, Net of
Taxes -- 248.0
Net Income $3,386.7 $3,577.4 N/M
Average Shares Outstanding
Assuming Dilution 2,231.2 2,261.6
Earnings per Common Share
Assuming Dilution
Continuing Operations $1.52 $1.47 3
Discontinued Operations -- 0.11
Total $1.52 $1.58 N/M
N/M Comparison not meaningful as a result of the spin-off of Medco Health.
* > 100%
(1) 2004 Marketing and administrative expense includes $55 million for restructuring costs.
(2) Research and development expense includes acquired research expense of $125 million resulting
from the acquisition of Aton Pharma, Inc. in 2004 and $90 million associated with the increase in
ownership of Banyu Pharmaceutical Co. Ltd. in 2003. Research and development expense also includes
licensing expense for research collaborations, including the initial payments of $70 million to Lundbeck in
the first quarter of 2004 and $100 million to Bristol-Myers Squibb and $20 million to Vertex in the second
quarter of 2004.
(3) The effective tax rate was 29.2% and 28.9% for the first six months of 2004 and 2003, respectively.
###